Approved for Maintenance treatment of bronchospasm associated with COPD, Rhinorrhea associated with allergic and nonallergic rhinitis (nasal spray). Ipratropium blocks muscarinic receptors in bronchial smooth muscle, preventing acetylcholine-mediated bronchoconstriction and mucus secretion. Side effects, costs, interactions, manufacturer, and generic alternatives sourced from FDA labels, openFDA…
Loading full data from Know Your Drugs Institute…